ArticleIrish journal of medical science2025
The effect of IL-17 and IL-23 ınhibitors on hematological ınflammatory parameters in patients with psoriasis vulgaris.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa-A Narrative Review.Dermatology and therapy · 2026Review
- Systemic Immune-Inflammation Index (SII) as a Predictive Biomarker of Therapeutic Response in Psoriasis: A Retrospective Comparative Analysis of Anti-TNF, Anti-IL-17, and Anti-IL-23 Agents.Journal of personalized medicine · 2026Article
- Neutrophil Albumin Ratio, Platelet Albumin Ratio, and Certain Inflammatory Parameters in Acne Vulgaris.Dermatology practical & conceptual · 2026Article
- The Dynamics of Blood-Count-Derived Inflammatory Indices in the Course of Systemic Treatment for Psoriasis: A Single Center Study.International journal of molecular sciences · 2026Article
- Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors.Journal of clinical medicine · 2026Article
- Tissue-Resident Memory T Cells in Rheumatoid Immune Diseases: Pathogenic Mechanisms and Therapeutic Strategies.Biomedicines · 2025Review
- Blood-Count-Derived Inflammatory Biomarkers and Characterization of Super-Responder Profile in Psoriatic Patients Receiving Biological Treatment: A Single-Center Study.International journal of molecular sciences · 2025Article
- Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study.Dermatology practical & conceptual · 2025Article
- Review
- Exploring immune-inflammation markers in psoriasis prediction using advanced machine learning algorithms.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveIL-17 and IL-23 inhibitors are widely used as biological agents in patients with psoriasis vulgaris to suppress inflammation and reduce disease severity. This study aimed to examine changes in inflammatory parameters, including neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic inflammation index (SII), platelet/hemoglobin ratio (PHR), and red cell distribution width/platelet ratio (RPR), as well as the Psoriasis Area and Severity Index (PASI), in psoriasis patients receiving biological therapy (IL-17 and IL-23 inhibitors). MATERIALS AND
methodsThis retrospective study included 110 patients with psoriasis vulgaris treated with IL-23 (risankizumab, guselkumab or IL-17 inhibitors ( secukinumab, and ixekizumab). Disease severity was assessed using the PASI score. Hematological parameters (NLR, PLR, SII, PHR, and RPR) and PASI values of the patients were recorded and analyzed at baseline (month 0) and during treatment (month 6).
resultsA significant decrease was observed in NLR, SII, and PHR values during treatment. NLR decreased significantly from 2.43 ± 1.25 at baseline to 2.12 ± 0.81 at month 6 (p = 0.002). Both IL-17 and IL-23 groups significantly reduced NLR (p = 0.044, p = 0.029, respectively). SII decreased significantly from 695 ± 390 at baseline to 588 ± 288 at month 6 (p = 0.002). Both groups significantly reduced SII levels (p = 0.044, p = 0.018, respectively).PHR decreased significantly from 19.8 ± 6.60 at baseline to 19.2 ± 6.58 at month 6 (p = 0.033).PASI score significantly decreased during treatment (p < 0.001).
conclusionThe significant reduction in NLR and SII levels in both the IL-17 and IL-23 groups suggests that these markers may be used together rather than separately in treatment follow-up. The significant decrease in PHR levels may indicate that IL-17 and IL-23 inhibitors contribute to reducing cardiovascular disease risk in patients with psoriasis vulgaris and promote a favorable long-term prognosis.
Indexed as
Identifiers
40455345What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.